Barclays analyst Etzer Darout raised the firm’s price target on CytomX Therapeutics (CTMX) to $6 from $3.50 and keeps an Overweight rating on the shares. The company’s data in late-line colorectal cancer compares favorably to peers, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- CytomX Therapeutics appoints Rachael Lester as chief business officer
- Oppenheimer positive on CytomX after Merus colon cancer data
- CytomX Therapeutics: Hold Rating Amid Awaited CX-801 Data and Market Potential
- CytomX Therapeutics initiated with an Overweight at Cantor Fitzgerald
- CytomX Therapeutics assumed with an Overweight at Barclays